Repatha Cost: List, Cash and Copay Card Prices

What you pay depends on how you fill it. Commercial insurance plus Amgen's copay card, Medicare Part D, and cash through AmgenNow each work differently. Prices at a glance:

In October 2025, Amgen launched AmgenNow and set the cash price at $239 a month, nearly 60% below list. You need a valid prescription, download a discount coupon through GoodRx, and fill it at a participating pharmacy. The program needs no prior authorization or step therapy, and it's open to everyone, including people with Medicare or Medicaid.

Read the conditions before you choose it. You agree not to submit the cost to your insurer. With Medicare Part D or another government plan, you also agree not to count the cost toward your deductible or out-of-pocket limit, and to buy all of that Amgen medicine through the program for the rest of the calendar year.

People with commercial insurance (through an employer or the marketplace) qualify once their plan approves Repatha. Amgen's program can lower the cost to as little as $5 for the first fill and each refill, up to program limits, with no income requirement.

The card isn't valid when Medicare, Medicaid or another federal or state program pays any part of the prescription. It helps only after insurance agrees to cover the drug, which usually means prior authorization.

Medicare Part D plans generally cover Repatha. In 2026, once you've spent $2,100 on covered drugs, your Part D plan pays 100% for the rest of the year.

Amgen reports that about 84% of Medicare Repatha prescriptions cost patients $50 or less a month, and people with the Part D Low Income Subsidy may pay $12.65 or less. Your own cost depends on your plan's tier.

Medicare plans usually require prior authorization too, with criteria similar to commercial plans.

Prior authorization means your insurer wants proof of need before it pays. Plans usually ask for a diagnosis, a recent LDL cholesterol (LDL-C) result, and documentation of your statin history.

One 2026 commercial policy, for example, asks for the highest tolerable statin dose for at least 12 weeks, or intolerance to at least two statins, or no ability to take statins. Follow your own plan's criteria.

A denial often asks for more information. Read the letter to see which criterion was missing, then file an internal appeal with the missing documents and a letter of medical necessity from your clinician. If that fails, most health plans must allow an independent external review. Ask your clinician to help with each step, and file promptly because deadlines apply.

No generic or biosimilar Repatha is sold in the US, and no launch date is public as of October 2026. Amgen's annual report lists US patents covering Repatha's antibodies through August 27, 2029 and its methods of treatment through May 10, 2032. A biosimilar also needs FDA approval.

Until then, the AmgenNow cash price is the lower-cost way to get Repatha itself. Cash prices for other medicines in the same drug class, as of October 2026, include Lerochol at $199 a month through LIB Therapeutics.